We work closely with other investigators at Cardiff University with a major focus on basic and translational research into haematological malignancies and clinical trials exploring innovative treatment for leukaemia.
Our research involves development of novel drugs, immunotherapies and other highly targeted approaches, including cellular therapies and molecularly directed agents, as well as the identification of genetic changes and molecular disease characteristics that can be exploited to direct patient-specific therapy.
Clinical research with expanding early phase clinical trial activity, molecular diagnostics and target identification is closely aligned with more basic laboratory research. The Haematology research groups work together across College themes to analyse various haematological cancers with respect to mechanisms of leukaemogenesis, leukaemic stem cells, drug development, animal models, microenvironmentally determined therapy resistance and novel cellular therapies.
These programmes are also closely linked with the research infrastructure in Cardiff, the National Cancer Research Institute (NCRI) Clinical Trials subgroups, as well as nationally and internationally with academic research centres and cooperative study groups for a broad spectrum of haematologic malignancies.
Our research programmes are supported by funding from government and charitable sources, including Medical Research Council, Health and Care Research Wales, CRUK, Bloodwise, Tenovus Cancer Care, Cancer Research Wales, Kay Kendall Leukaemia Fund and Leukaemia Research Appeal for Wales.
Area of interest
The development of novel drugs and highly targeted approaches, including immunotherapies and molecularly directed agents. He has served as principal investigator on numerous national and international first in human, phase I, II, and III clinical studies of many novel agents.
Principal members of staff
|Name||Area of interest|
|Professor Richard Darley||Research in acute myeloid leukaemia|
|Professor Christopher Fegan||Chronic lymphocytic leukaemia trials and translational research and early phase leukaemogenesis|
|Dr Steve Knapper||Acute myeloid leukemia (AML) trials in myeloid malignancies|
|Dr Alex Tonks||Research in acute myeloid leukaemia|
|Dr Keith Wilson||Clinical stem cell transplantation|
|Dr Caroline Alvares||Acute myeloid leukemia (AML) trials and research on microenvironment|
|Dr Stephen Man||Immunology research on lymphoid malignancies|
|Dr Joanna Zabkiewicz||Translational drug development and microenvironmental research|
|Dr Martin Ruthardt||Leukaemogenesis and Oncogenic fusion Genes|
Our research creates benefits across health, society and the economy.